Fig. 5

The inoculum dosage of recombinant MCMV-based vaccine vectors determines the magnitude of anti-tumor T cell response and protection efficacy. a Schematic of the experiment. Mice were infected with indicated doses and routes or kept unvaccinated. After 35 days, all the mice were challenged with TC-1 tumor cells. The tumor outgrowth and survival of the mice was followed for 60 days. b Percentage of E7-specific and the percentage of EM-like cells within the E7-specific CD8⁺ T cells of the vaccinated mice. c and d TC-1 tumor outgrowth (c) and survival (d) graphs of mice immunized with MCMV-IE2-E7 (schematic shown in a). The number of tumor-free/total mice is indicated above each tumor out growth graph in (c). Tumor out growth was followed for 60 days. The number of tumor-free/total mice is indicated. *, P < 0.05; **, P < 0.01; ***, P < 0.001